COMPANY
IDEAYA Biosciences
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Director, Intellectual Property | South San Francisco HQ | Oct 21, 2026 | Oct 7, 2026 |
| Senior Research Scientist, Medicinal Chemistry | South San Francisco HQ | Oct 20, 2026 | Oct 7, 2026 |
| Principal Research Scientist, Analytical Chemistry | South San Francisco HQ | Oct 15, 2026 | Oct 7, 2026 |
| Director, CMC Process Chemistry | South San Francisco HQ | Oct 15, 2026 | Oct 7, 2026 |
| Director, Good Manufacturing Processes, Quality Assurance | South San Francisco HQ | Sep 30, 2026 | Oct 5, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (36 open jobs at last check). source ↗
- Trial start Phase 3: Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma source ↗
- Trial start Phase 1: A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors source ↗
- Trial start Phase 1: A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors source ↗
- Trial start Phase 1: A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types source ↗
- Trial start Phase 3: Neoadjuvant Darovasertib in Primary Uveal Melanoma source ↗
- Trial start Phase 1/Phase 2: A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer source ↗
- Partnership Partnership / licensing announced Dec 29, 2024. Source: SEC filing. source ↗
- Trial start Phase 2/Phase 3: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma source ↗
- Trial start Phase 2: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma source ↗
- Trial start Phase 1: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors source ↗
- Trial start Phase 1: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion source ↗
- Trial start Phase 1/Phase 2: Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions source ↗
Upcoming milestones
- 2026-10 (ESTIMATED) · Phase 1 · A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors · NCT05787587
- Jan 7, 2027 (ESTIMATED) · Phase 1 · Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion · NCT04794699
- Jan 15, 2027 (ESTIMATED) · Phase 2/Phase 3 · IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma · NCT05987332
- Jan 29, 2027 (ESTIMATED) · Phase 1/Phase 2 · Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions · NCT03947385
- Apr 30, 2027 (ESTIMATED) · Phase 2 · (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma · NCT05907954
- Jul 30, 2027 (ESTIMATED) · Phase 1 · A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · NCT07503808
- Apr 30, 2028 (ESTIMATED) · Phase 1 · A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · NCT07277413
- 2029-07 (ESTIMATED) · Phase 1/Phase 2 · A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer · NCT07174583
Open jobs 36
Funding
- Partnership / licensing announced Dec 29, 2024. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 11
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase 1 | Recruiting | Mar 4, 2026 | Apr 30, 2028 (estimated) |
| NCT07804186 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | Phase 3 | Recruiting | 2026-09 | 2034-03 (estimated) |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | Active, not recruiting | Apr 18, 2023 | 2026-10 (estimated) |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/Phase 2 | Recruiting | Oct 14, 2025 | 2029-07 (estimated) |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | Phase 1 | Recruiting | Feb 24, 2026 | Jul 30, 2027 (estimated) |
| NCT07540572 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | Phase 1 | Recruiting | Mar 17, 2026 | Mar 30, 2030 (estimated) |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/Phase 2 | Recruiting | Jun 28, 2019 | Jan 29, 2027 (estimated) |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | Recruiting | Jan 25, 2026 | 2030-10 (estimated) |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase 1 | Active, not recruiting | Apr 14, 2021 | Jan 7, 2027 (estimated) |
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase 2 | Active, not recruiting | Jul 3, 2023 | Apr 30, 2027 (estimated) |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/Phase 3 | Active, not recruiting | Oct 31, 2023 | Jan 15, 2027 (estimated) |
Connect
See your connections at IDEAYA Biosciences on LinkedIn (search by name, results not checked)